TD to Expand its U.S. Investment Banking Business and Capabilities with Acquisition of Cowen Inc. Click here for the Press Release

$100 Million

Urogen Pharma, Ltd.

Sole Placement Agent & Exclusive Financial Advisor, March 2022

Senior Secured Term Loan

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means.

More Like This

Aug 2022
$60 Million

Sr. Secured Term Loan

Sole Placement Agent & Exclusive Financial Advisor

View Details
Jul 2022
$264.5 Million
Revolution Medicines logo

Follow-on Offering

Bookrunner

View Details
Jul 2022
$500 Million

Royalty Purchase Agreement (Partial Monetization)

Exclusive Financial Advisor

View Details